Recapture and retreatment rates with ixekizumab after withdrawal of therapy in patients with axial spondyloarthritis: results at week 104 from a randomised placebo-controlled withdrawal study.

Robert B M Landewé,Denis Poddubnyy,Proton Rahman,Filip E Van den Bosch,Rebecca Bolce,Soyi Liu Leage,Jeffrey R Lisse,So Young Park,Lianne Gensler

Annals of the rheumatic diseases（2023）

引用 0|浏览18

暂无评分

摘要

Ninety-six per cent of patients withdrawn to placebo recaptured at least ASDAS LDA and 71% recaptured ASDAS ID with IXE retreatment at week 104. This may provide support to patients who may require a brief interruption in therapy.

查看译文

关键词

Antirheumatic Agents,Biological Therapy,Immune System Diseases,Spondylitis, Ankylosing

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要